Collect

SST/Gold Top
Minimun Volume:  0.5 -1.0 ml of serum
 

Specimen Preparation

Allow serum tube to clot completely at room temperature for a minimum of 20 mins. Separate serum from cells within 2 hours of collection. (Min: 0.3 mL serum or plasma)

Storage/Transport Temperature

Refrigerated.

Stability (from collection to initiation)

After separation from cells:
  • Room temperature  (15 to 30°C) – 2 days
  • Refrigerated at 2‑8 °C - 7 days
  • Frozen (- ≤20 °C) – Longer stability

Cerner Orderable(s)

COVID 19 IgM Antibody

Performed

St. Joseph's Hospital 

Methodology

Chemiluminescent

Reported

Within 24 - 48 hours.

Synonyms

  • SARS-CoV-2

Reference Interval

Negative

 

Interpretive Data

Comment:
This test detects IgM antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has received Emergency Use Authorization (EUA) from the FDA. A negative result does not rule out active /recent COVID-19 Follow-up testing with a molecular test is recommended in symptomatic patients. A positive result suggests a recent infection with SARS-CoV-2. Infrequently, false-positive results may be due to prior infection with other human coronaviruses.
Collection

Collect

SST/Gold Top
Minimun Volume:  0.5 -1.0 ml of serum
 

Specimen Preparation

Allow serum tube to clot completely at room temperature for a minimum of 20 mins. Separate serum from cells within 2 hours of collection. (Min: 0.3 mL serum or plasma)

Storage/Transport Temperature

Refrigerated.

Stability (from collection to initiation)

After separation from cells:
  • Room temperature  (15 to 30°C) – 2 days
  • Refrigerated at 2‑8 °C - 7 days
  • Frozen (- ≤20 °C) – Longer stability
Ordering

Cerner Orderable(s)

COVID 19 IgM Antibody

Performed

St. Joseph's Hospital 

Methodology

Chemiluminescent

Reported

Within 24 - 48 hours.

Synonyms

  • SARS-CoV-2
Result Interpretation

Reference Interval

Negative

 

Interpretive Data

Comment:
This test detects IgM antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has received Emergency Use Authorization (EUA) from the FDA. A negative result does not rule out active /recent COVID-19 Follow-up testing with a molecular test is recommended in symptomatic patients. A positive result suggests a recent infection with SARS-CoV-2. Infrequently, false-positive results may be due to prior infection with other human coronaviruses.
Administrative